GlassScriptPhysician profile
Dean J Mariano
NPI 1972595874
$2,140.98
in general payments reported to CMS, 2019-2025
14 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,344 · 2022: $216 · 2023: $173 · 2024: $264 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $580.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $1,344.30 | 2019 | |
| Amgen INC. | $137.63 | 2022-2024 | Evenity, Prolia |
| Teva Pharmaceuticals USA, INC. | $120.41 | 2025 | Austedo Xr |
| Impel Pharmaceuticals INC. | $114.05 | 2023 | Trudhesa |
| Ani Pharmaceuticals, INC. | $113.36 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $103.85 | 2022 | |
| Boston Scientific Corporation | $72.24 | 2023-2025 | General - Pain Management |
| Grt US Holding, INC. | $23.59 | 2022 | |
| Lilly USA, LLC | $21.43 | 2023 | Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.01 | 2023 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $19.50 | 2022 | |
| Neurocrine Biosciences, INC. | $17.17 | 2022 | |
| Merck Sharp & Dohme LLC | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Mariano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.